Analysts See $-0.96 EPS for RXi Pharmaceuticals Corporation (RXII)

March 15, 2018 - By Louis Casey

 Analysts See $ 0.96 EPS for RXi Pharmaceuticals Corporation (RXII)

Analysts expect RXi Pharmaceuticals Corporation (NASDAQ:RXII) to report $-0.96 EPS on March, 29.They anticipate $5.04 EPS change or 84.00 % from last quarter’s $-6 EPS. After having $-1.10 EPS previously, RXi Pharmaceuticals Corporation’s analysts see -12.73 % EPS growth. The stock increased 42.19% or $1.35 during the last trading session, reaching $4.55. About 1.00M shares traded or 306.49% up from the average. RXi Pharmaceuticals Corporation (NASDAQ:RXII) has declined 75.22% since March 15, 2017 and is downtrending. It has underperformed by 91.92% the S&P500.

RXi Pharmaceuticals Corporation, a clinical-stage company, focuses on developing therapeutics for unmet medical needs. The company has market cap of $10.78 million. It develops therapies based on its self-delivering RNAi platform; and Samcyprone topical immunomodulatory. It currently has negative earnings. The company's clinical development programs include RXI-109, an sd-rxRNA compound, which is in Phase II clinical trial for preventing or reducing dermal scarring following scar revision surgery of an existing hypertrophic scar; and in Phase I/II clinical trial for treating retinal scarring, as well as in discovery stage for the treatment of corneal scarring.

More notable recent RXi Pharmaceuticals Corporation (NASDAQ:RXII) news were published by: which released: “RXi Pharmaceuticals Enters into Exclusive Option Agreement to Acquire …” on October 12, 2016, also with their article: “RXi Pharmaceuticals Enters into Common Stock Purchase Agreement for Up to $15 …” published on August 09, 2017, published: “RXi Pharmaceuticals Corp. RXII (US: Nasdaq)” on February 11, 2011. More interesting news about RXi Pharmaceuticals Corporation (NASDAQ:RXII) were released by: and their article: “RXi Pharmaceuticals Completes Acquisition of MirImmune Inc. and Appoints New …” published on January 09, 2017 as well as‘s news article titled: “RXi Pharmaceuticals Corp: Building a Foundation for a Breakout” with publication date: November 18, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: